依法利珠单抗治疗期间银屑病病情加重。
Exacerbation of psoriasis under efalizumab therapy.
作者信息
Rallis Efstathios, Verros Constantinos, Karanikola Evmorfia, Valaskatzi Argyro, Papaconstantis Markos
机构信息
Department of Dermatology, Army General Hospital, Athens, Greece.
出版信息
J Cutan Med Surg. 2009 Mar-Apr;13(2):106-9. doi: 10.2310/7750.2008.07087.
BACKGROUND
Efalizumab is a recombinant humanized IgG1-kappa isotype monoclonal antibody that binds to CD11a, inhibiting T-cell activation. It has been approved for the treatment of moderate to severe plaque psoriasis. Efalizumab has been associated with the development of skin eruptions during the administration period, and this probably represents the potential psoriasis events observed during its administration.
OBJECTIVE
We report a case of exacerbation of psoriasis under efalizumab administration. A reversible increase in lymphocyte count with normal total white blood cell count was also noticed.
CONCLUSION
Larger series are probably needed to establish clinical and histopathologic criteria and to determine the terminology used regarding the psoriasis adverse events seen with efalizumab treatment.
背景
依法利珠单抗是一种重组人源化IgG1-κ同种型单克隆抗体，可与CD11a结合，抑制T细胞活化。它已被批准用于治疗中度至重度斑块状银屑病。依法利珠单抗在给药期间与皮疹的发生有关，这可能代表了在其给药期间观察到的潜在银屑病事件。
目的
我们报告1例依法利珠单抗给药后银屑病加重的病例。同时还注意到淋巴细胞计数可逆性增加而总白细胞计数正常。
结论
可能需要更大规模的系列研究来确立临床和组织病理学标准，并确定用于描述依法利珠单抗治疗中出现的银屑病不良事件的术语。
Zotero 插件